← Leaderboards
James L Miller
Stategics, Inc.
$757,911
Attributed
$1,789,707
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $738.4K · FY2017–21$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,789,707 · 2
By mechanism
R44$1,547,694 · 1
R43$242,013 · 1
Top collaborators
- Jon E Hawkinson3 shared
- Jeffrey R Spencer3 shared
Most similar at Stategics, Inc.
Same institution · by research overlap
- Jeffrey R Spencer$773,455
- Juha Punnonen$415,275
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoParkinson DiseaseExtracellular DomainIn VitroLibrariesOralEpor GeneErythropoietin ReceptorFrataxinHigh Throughput ScreeningCytoprotectionLeadMethodologyMinnesotaCellsBioavailableAssay DevelopmentClinical ResearchBaseFluorescence Resonance Energy TransferFriedreich AtaxiaFutureBindingPre-Clinical
Grant awards (4)
Homogeneous Screening Assay for Cytokine Receptor Modulators$86,761
R44 · FY2021 · TR
Homogeneous Screening Assay for Cytokine Receptor Modulators$738,401
R44 · FY2020 · TR
Homogeneous Screening Assay for Cytokine Receptor Modulators$722,532
R44 · FY2019 · TR
Development of a Homogeneous Screening Assay for the Tissue-Protective EPOR$242,013
R43 · FY2017 · TR · contact PI